AI Article Synopsis

  • Pseudoxanthoma elasticum (PXE) is a rare genetic disease that leads to calcification in the arteries of young individuals, requiring complex multi-organ analysis or genetic testing for diagnosis.
  • Researchers developed a new method to accurately measure plasma inorganic pyrophosphate (PPi) levels in PXE patients and identified a cutoff value that enhances diagnosis.
  • In a study involving 153 PXE patients, they found that lower PPi levels (average of 0.92 µmol/L) compared to non-PXE patients (1.61 µmol/L) were strongly associated with PXE, indicating that plasma PPi measurement could be a reliable blood test for diagnosing this condition.

Article Abstract

Pseudoxanthoma elasticum (PXE) is a rare inherited systemic disease responsible for a juvenile peripheral arterial calcification disease. The clinical diagnosis of PXE is only based on a complex multi-organ phenotypic score and/or genetical analysis. Reduced plasma inorganic pyrophosphate concentration [PPi]p has been linked to PXE. In this study, we used a novel and accurate method to measure [PPi]p in one of the largest cohorts of PXE patients, and we reported the valuable contribution of a cutoff value to PXE diagnosis. Plasma samples and clinical records from two French reference centers for PXE (PXE Consultation Center, Angers, and FAVA-MULTI South Competent Center, Nice) were assessed. Plasma PPi were measured in 153 PXE and 46 non-PXE patients. The PPi concentrations in the plasma samples were determined by a new method combining enzymatic and ion chromatography approaches. The best match between the sensitivity and specificity (Youden index) for diagnosing PXE was determined by ROC analysis. [PPi]p were lower in PXE patients (0.92 ± 0.30 µmol/L) than in non-PXE patients (1.61 ± 0.33 µmol/L, < 0.0001), corresponding to a mean reduction of 43 ± 19% (SD). The PPi cutoff value for diagnosing PXE in all patients was 1.2 µmol/L, with a sensitivity of 83.3% and a specificity of 91.1% (AUC = 0.93), without sex differences. In patients aged <50 years (i.e., the age period for PXE diagnosis), the cutoff PPi was 1.2 µmol/L (sensitivity, specificity, and AUC of 93%, 96%, and 0.97, respectively). The [PPi]p shows high accuracy for diagnosing PXE; thus, quantifying plasma PPi represents the first blood assay for diagnosing PXE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11203691PMC
http://dx.doi.org/10.3390/ijms25126502DOI Listing

Publication Analysis

Top Keywords

pxe patients
12
pxe
11
cutoff diagnosing
8
pseudoxanthoma elasticum
8
plasma samples
8
non-pxe patients
8
diagnosing pxe
8
patients
6
plasma
5
plasma pyrophosphate
4

Similar Publications

A diagnosis of age-related macular degeneration (AMD) may have a significant impact on a patient's life. Therefore, it is important to consider differential diagnoses, as these can differ considerably from AMD regarding prognosis, inheritance, monitoring and therapy. Differential diagnoses include other macular diseases with drusen, drusen-like changes, monogenic retinal dystrophies, as well as a wide range of other, often rare macular diseases.

View Article and Find Full Text PDF

Background: Pseudoxanthoma elasticum (PXE) is characterized by aberrant calcification of elastic tissues throughout the body causing varying degrees of skin, cardiac, and ocular disease. Although PXE is classically regarded as an autosomal recessive disease, recent reports have demonstrated a haploinsufficiency phenotype, in which carriers of monoallelic ATP-binding cassette transporter () gene mutations demonstrate mild manifestations of PXE. In this case report, we describe a patient with a monoallelic mutation and atypical angioid streaks.

View Article and Find Full Text PDF

Background/aim: Pseudoxanthoma elasticum (PXE) is a genetic connective tissue disorder that affects the skin with limited treatment options. A recent technology employing particle-free polycaprolactone (PCL) has shown promising results in treating inner thighs and kness of a 27-year-old female patient. This article provides a case report along with our detailed treatment protocol based on the efficacy of PCL in reversing skin laxity that can be easily incorporated into the therapeutic approaches for patients with PXE.

View Article and Find Full Text PDF

Fibroelastolytic papulosis (FEP) is an acquired cutaneous disorder of elastin that encompasses both white fibrous papulosis of the neck (WFPN) and pseudoxanthoma elasticum (PXE)-like papillary dermal elastolysis (PDE). Although FEP is a benign acquired disorder, it shares overlapping clinical features with pseudoxanthoma elasticum (PXE), a genetic disorder with systemic manifestations. We report two cases of FEP, including the WFPN and PXE-like PDE variants, in elderly women.

View Article and Find Full Text PDF
Article Synopsis
  • Pseudoxanthoma elasticum (PXE) is a rare genetic disorder that leads to abnormal calcium deposits in elastic tissue, causing skin changes and other health issues.
  • The study focused on a 13-year-old patient with flare-ups in PXE lesions, leading to a closer examination of the inflammation involved through skin biopsies and various analyses.
  • Findings showed inflammation with T-cell infiltrates in the skin, particularly with a Th1 response, suggesting an inflammatory role in PXE disease, but the exact impact on the condition needs more research.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!